Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 23;24(1):424.
doi: 10.1186/s12876-024-03523-1.

The diagnositic value of dynamic contrast-enhanced ultrasound for evaluation of tissue oxygen status in rat hepatoma model

Affiliations

The diagnositic value of dynamic contrast-enhanced ultrasound for evaluation of tissue oxygen status in rat hepatoma model

Bo Jiang et al. BMC Gastroenterol. .

Abstract

Background: Hypoxia is a characteristic of solid tumors, but whether significant hypoxia exists in the hepatocellular carcinoma remains unclear. This animal study aims to explore the value of dynamic contrast-enhanced ultrasound (CEUS) quantitative parameters to evaluate the oxygen status in two rat hepatoma models.

Materials and methods: N1S1 and McA-RH7777 S-D rat orthotopic hepatoma models were established. Once the tumors reached a diameter of 10-15 mm, CEUS and oxygen partial pressure (pO2) polarography were performed. Immunohistochemical staining for HIF-1α and pimonidazole was conducted after euthanizing the rats. Correlation between quantitative CEUS parameters, pO2, and the immunohistochemical integrated optical density (IOD) was analyzed to assess the predictive ability of CEUS quantitative parameters for the tissue oxygen environment.

Result: Eleven N1S1 models and ten McA-RH7777 models were established successfully. There was no significant difference in pO2 (35.5 mmHg vs 32.2 mmHg, P = 0.917), IOD of HIF-1α (13.4 vs 20.0, P = 0.159) and pimonidazole (0.70 vs 1.30, P = 0.926) between the tumor and the peritumoral liver tissue. The pO2 values were correlated with CEUS quantitative parameters including mean time-intensity curves (mTIC) (P = 0.003), peak intensity (PKI) (P = 0.010), area under the curve (AUC) (P = 0.009), area under the wash-in curve (WiAUC) (P = 0.006), and arrival time (AT) (P = 0.033). The IOD of HIF-1α correlated with AUC (P = 0.022), WiAUC (P = 0.009), ascending slope (AS) (P = 0.044), and falling time (FT) (P = 0.009). Multiple linear regression indicated that the "short AT" was an independent protective factor for hypoxia (β = -2.347, 95% CI: -4.948, -0.394, P = 0.022), and CEUS had the ability to predict the tumor pO2 (P = 0.003).

Conclusion: No evidence of significant hypoxia was identified in two rat orthotopic hepatoma models. Quantitative CEUS parameters correlated with the oxygen status of the tumor, which could be utilized to predict the tumor tissue pO2.

Keywords: Hypoxia; Liver neoplasm; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This animal study was approved by Animal Care and Ethics Committee of the First Medical Center of PLA General Hospital (No. 2023-X19-90). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The schematic diagram shows the experimental procedure in this study. A Animal modeling and monitoring. Two orthotopic hepatoma (N1S1 and McA-RH7777) Sprague–Dawley rat models were established. After models were established, B-mode ultrasound was used to monitor the growth of the hepatoma; B Dynamic CEUS image acquisition and quantitative CEUS parameter analysis; C Tissue oxygen partial pressure measurement by polarography method. Under the guidance of ultrasound, the oxygen electrode was inserted into the corresponding position of CEUS observation. The pO2 value of hepatoma and peritumoral liver parenchyma was recorded; D Pathological and immunohistochemical examination. After the hepatoma was harvested, WSI was obtained according to the section of CEUS observation. CEUS: contrast-enhanced ultrasound; IOD was analyzed WSI: whole-slide images; IOD: integrated optical density
Fig. 2
Fig. 2
Examples of ultrasound image acquisition, quantitative parameter analysis, and oxygen partial pressure measurement. A The length and height of the tumors were measured by two-dimensional ultrasound; B The width of the tumor was measured by two-dimensional ultrasound; C CDFI showed abundant blood flow signals in the tumor; D The peritumoral liver parenchyma, the whole tumor area and different subregions of the tumor were delineated, and their parametric imaging, enhancement curves were shown. E CEUS quantitative parameters were shown. F Under the guidance of ultrasound, the oxygen electrode was inserted into the superficial layer of the tumor, corresponding to the green circle area (Fig. 3E). CDFI: Color Doppler flow imaging; CEUS: contrast-enhanced ultrasound
Fig. 3
Fig. 3
The violin plot illustrates the distribution of oxygen partial pressure values in the different models. A The pO2 value of all hepatoma and peritumoral liver parenchyma; B The pO2 value of N1S1 tumor and peritumoral liver parenchyma; C The pO2 value of McA-RH7777 tumor and peritumoral liver parenchyma
Fig. 4
Fig. 4
Correlation between the IOD of hypoxia markers and CEUS quantitative parameters. A Linear correlation between IOD of HIF-1α and AUC; B Linear correlation between IOD of HIF-1α and WiAUC; C Linear correlation between IOD of HIF-1α and AS; D Linear correlation between IOD of HIF-1α and FT; E HIF-1α was weekly expressed in the perinecrotic part of the tumor; F Pimonidazole was weekly expressed in the perinecrotic part of the tumor; G HIF-1α was not obviously expressed in tumors without necrosis; H Pimonidazole was not obviously expressed in tumors without necrosis

Similar articles

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. - PubMed
    1. Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(4):310–22. - PubMed
    1. Abou-Alfa GK, Geyer SM, Nixon AB, Innocenti F, Shi Q, Kumthekar P, Jacobson S, El Dika I, Yaqubie A, Lopez J, et al. CCALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma. Cancer Res Commun. 2024;4(3):682–90. - PMC - PubMed
    1. Bao MH, Wong CC. Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715. - PMC - PubMed
    1. Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med. 2018;50(10):1–9. - PMC - PubMed

MeSH terms

LinkOut - more resources